EUVIMEDEUVIMED entdecken
Crossref

Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment

Madhumitha Haridoss, Akhil Sasidharan, Sajith Kumar, Kavitha Rajsekar, Krishnamurthy Venkataraman, Bhavani Shankara Bagepally iD

Applied Health Economics and Health Policy · 2024-11 · 22 (6) · 885-896

DOI: 10.1007/s40258-024-00898-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Health Economics and Health Policy, online erschienen am 01.07.2024. Verfasst von Madhumitha Haridoss und 5 weiteren Autor:innen. Beteiligte Einrichtung: Health Technology Assessment Resource Centre, ICMR-National Institute of Epidemiology, R-127, Tamil Nadu Housing Board, Phase I and II, Ayapakkam, Ch…. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Cost-Benefit Analysis, Janus Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Department of Health Research, Govt of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Rheumatoid arthritis (RA) is a progressive and debilitating disease, causing persistent joint pain that limits daily activities requiring long-term treatment. Newer targeted therapies expand RA treatment options, but their high cost necessitates a focus on cost effectiveness. To address this, we aim to conduct a cost-utility analysis of these newer RA pharmacotherapies to support evidence-based policy decision-making. METHODS: We analyzed the cost-utility of sequential treatment with TNF-α, B cell and JAK-inhibitors compared with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for RA treatment in methotrexate (MTX) nonresponders. We used a Markov model with lifetime horizon and 6-month cycles from an Indian health system perspective. Costs (INR 2022) and quality-adjusted life years (QALYs) were used to determine the incremental cost-effectiveness ratios (ICERs) at a cost-effectiveness threshold of India's gross domestic product (GDP) per capita (2022). We assessed uncertainty using univariate, probabilistic sensitivity, and scenario analyses. RESULTS: Despite additional QALYs, TNF-α, B cell, and JAK inhibitors were not cost-effective for treating moderate-to-severe patients with RA unresponsive to csDMARDs (including MTX) in India, as increased costs outweighed their clinical benefits. ICERs ranged from 10,46,206 to 31,09,207 Indian Rupees in the base case analysis, exceeding three times India's GDP per-capita [approximately USD $13,287 to $39,487 and GBP £10,776 to £32,025]. Sensitivity analyses confirmed the results' robustness. Scenario analysis suggested that a cost reduction of over 75% in drug prices could make most of the interventions cost effective compared with csDMARDs. CONCLUSIONS: TNF-α, B cell, and JAK-inhibitors are not cost-effective compared with csDMARDs for patients with RA who have not responded to MTX in India at the current prices. Cost-effectiveness estimates were highly influenced by drug pricing variations. Therefore, reducing the prices of these interventions could enhance affordability, potentially leading to their inclusion in publicly funded health programs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidCost-Benefit AnalysisJanus Kinase InhibitorsTumor Necrosis Factor-alphaFemaleHumansMaleMiddle AgedB-LymphocytesIndiaMarkov ChainsMethotrexateQuality-Adjusted Life Years

Substanzen

Antirheumatic AgentsJanus Kinase InhibitorsMethotrexateTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Health Technology Assessment Resource Centre, ICMR-National Institute of Epidemiology, R-127, Tamil Nadu Housing Board, Phase I and II, Ayapakkam, Chennai, 600077, India.
  • Division of Medical Research, SRM Medical College, Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, 603203, India.
  • Health Technology Assessment in India (HTAIn) Secretariat, Department of Health Research, MoHFW, GOI, New Delhi, India.
  • Chennai Meenakshi Multispeciality Hospital, Chennai, India.
  • Health Technology Assessment Resource Centre, ICMR-National Institute of Epidemiology, R-127, Tamil Nadu Housing Board, Phase I and II, Ayapakkam, Chennai, 600077, India. bagepally.bs@gov.in.

ORCID-Profile: Bhavani Shankara Bagepally

Förderung

  • Department of Health Research, Govt of India

Zitieren

APA

Haridoss, M., Sasidharan, A., Kumar, S., Rajsekar, K., Venkataraman, K., & Bagepally, B. S. (2024). Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment. Applied Health Economics and Health Policy, 22(6), 885-896. https://doi.org/10.1007/s40258-024-00898-w

Vancouver

Haridoss M, Sasidharan A, Kumar S, Rajsekar K, Venkataraman K, Bagepally BS. Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment. Applied Health Economics and Health Policy. 2024;22(6):885-896. doi:10.1007/s40258-024-00898-w

BibTeX
@article{Haridoss2024,
  author = {Haridoss, Madhumitha and Sasidharan, Akhil and Kumar, Sajith and Rajsekar, Kavitha and Venkataraman, Krishnamurthy and Bagepally, Bhavani Shankara},
  title = {Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment},
  journal = {Applied Health Economics and Health Policy},
  year = {2024},
  volume = {22},
  number = {6},
  pages = {885--896},
  doi = {10.1007/s40258-024-00898-w}
}
Kostenlos starten →